We reasoned that the CAR-Ms did not need to stay in the tumor for the entirety of the experiment, but CAR-Ms must be present in the tumor long enough to phagocytose CSPG4-positive melanoma cells and potentially reprogram the tumor environment for a sustained response. The gene discussed is CSPG4; the disease is melanoma.